Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27818073 | 0.82 | TSHR (0.57) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL11271367 | 0.81 | TSHR (0.55) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL9799560 | 0.79 | TSHR (0.63) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL2026026 | 0.79 | TSHR (0.63) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL27999815 | 0.79 | TSHR (0.53) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL11228427 | 0.79 | TSHR (0.49) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL27627130 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL16165882 | 0.78 | TSHR (0.52) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL9763714 | 0.78 | TSHR (0.52) | TSHRALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL2949251 | 0.78 | TSHR (0.61) | TSHRALDH1A1L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101787000-B | M-stage kinesin inhibitor | KYOWA HAKKO KOGYO KK | 2011-08-03 | — | — | CN | disclosed |
| CN-101787000-A | M-stage kinesin inhibitor | KYOWA HAKKO KOGYO KK | 2010-07-28 | — | — | CN | disclosed |
| CN-1774428-B | M-phase kinesin inhibitors | KYOWA HAKKO KOGYO KK | 2010-06-16 | — | — | CN | disclosed |
| CN-1774428-A | M-phase kinesin inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2006-05-17 | — | — | CN | disclosed |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| EP-0473698-B1 | METHOD OF PREPARING D-PROPOXYPHENE | MALLINCKRODT INC (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5312970-A | Method of preparing D-propoxyphene | MALLINCKRODT SPECIALTY CHEMICALS COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| US-4661625-A | Synthesis and purification of d-propoxyphene hydrochloride | MALLINCKKODT, INC. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | TSHR 3929/4885ALDH1A1 290/4885L3MBTL1 4174/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | TSHR 4216/4885ALDH1A1 530/4885L3MBTL1 4527/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | TSHR 3606/4885ALDH1A1 133/4885L3MBTL1 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.